BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Epilepsy gene therapy deal ‘Sparks’ 172% stock surge at Combigene
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Epilepsy gene therapy deal ‘Sparks’ 172% stock surge at Combigene
Oct. 12, 2021
By
Cormac Sheridan
No Comments
Dublin – Shares in Combigene AB, a little-known Swedish gene therapy firm, surged upward by 172% Oct. 12 on news of a preclinical licensing deal in epilepsy with Spark Therapeutics, which is potentially worth $328.5 million.
BioWorld
Deals and M&A
Neurology/psychiatric
Gene therapy